Resources Repository
-
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Preferences/Values | Costing Methods | Health/Medicine | Economics/Finance | Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Policy/Regulation | Government/Law | North America -
ReportPublication 2018Estimating the Distributional Impact of Increasing Taxes on Tobacco Products in Armenia
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors …
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors conducted an extended cost-effectiveness analysis (ECEA) on increases in the excise tax on cigarettes in Armenia. Based on the World Health Organization recommendations, they analyzed the impact of a 75% increase of excise tax on the retail price of cigarettes. The ECEA found large health and financial benefits to the excise tax. It averted about 88,000 premature deaths, US$63 million of OOP…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Europe -
ReportPublication 2015Returns on HTA Funded Research
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) …
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) program in making quality research accessible and cost-effective. The authors conduct an economic analysis to illustrate benefits of new interventions in two ways: through improved health, measured in QALYs, and through showing that the intervention allows for the same health outcome and a lower cost. The report utilizes economic analyses and case studies to make recommendations. These recommendations include considering…
Evidence Synthesis | Costing Methods | Health/Medicine | Economics/Finance | Health Outcomes | Health Systems | Science/Technology | Europe -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Priority Setting/Ethics | Mathematical Models | Cost-Effectiveness Analysis | Costing Methods | Health/Medicine | State-Transition | Microsimulation | Decision Analysis | Chronic Disease/Risk | Mental Health | Latin America & Caribbean -
ReportPublication 2014Redirecting Innovation in U.S. Health Care
This report from RAND Health explores methods of reducing health care spending and developing medical …
This report from RAND Health explores methods of reducing health care spending and developing medical products that provide cost value with health benefits. It summarizes literature and explores case studies to provide policy recommendations to meet these goals. It identifies a wide range of factors that affect the costs, risks, and rewards of medical product invention. Some of these features include treatment creep, the medical arms race, costs and risks of FDA approval, limited reward…
Evidence Synthesis | Costing Methods | Health/Medicine | Economics/Finance | Health Outcomes | Health Systems | Policy/Regulation | Government/Law | Science/Technology | North America -
ReportPublication 2017Communicating Science Effectively: A Research Agenda
Science and technology are embedded in virtually every aspect of modern life. As a result, …
Science and technology are embedded in virtually every aspect of modern life. As a result, people face an increasing need to integrate information from science with their personal values and other considerations as they make important life decisions about medical care, the safety of foods, what to do about climate change, and many other issues. Communicating science effectively, however, is a complex task and an acquired skill. Moreover, the approaches to communicating science that will…
Priority Setting/Ethics | Preferences/Values | Decision Psychology | Health/Medicine | Social Determinants | Climate/Environment | Culture/Society | Energy/Engineering | Education/Labor | Science/Technology | North America -
ReportPublication 2017DCP3: Cardiovascular, Respiratory, and Related Disorders
This report from the World Bank is the fifth volume of the Disease Control Priorities, …
This report from the World Bank is the fifth volume of the Disease Control Priorities, Third Edition (DCP3) series. It addresses the disease burden of cardiovascular, respiratory, and related disorders (CVRDs), which account for more than half of global adult deaths, mostly in low- and middle-income countries. While CVRDs are mostly preventable or can be treated to reduce morbidity, such interventions are costly and require greater capacity to detect and treat early. When combined with…
Evidence Synthesis | Cost-Effectiveness Analysis | Costing Methods | Health/Medicine | Health Outcomes | Chronic Disease/Risk | Social Determinants | Health Systems | Global Governance | Climate/Environment | Global -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Evidence Synthesis | Preferences/Values | Cost-Effectiveness Analysis | Health/Medicine | Health Outcomes | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Science/Technology | North America -
ReportPublication 2023Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health
This ISPOR Task Force report examines the integration of patient preferences into healthcare decision-making, emphasizing …
This ISPOR Task Force report examines the integration of patient preferences into healthcare decision-making, emphasizing the growing significance of both qualitative and quantitative methods for studying these preferences. The report synthesizes current best practices to enhance the utility and impact of patient-preference studies. The methods involved reviewing existing literature and practices to construct the ISPOR Roadmap for Patient Preferences in Decision Making. This roadmap encourages collaboration among researchers, decision-makers, patients, patient groups, and other stakeholders.…
Evidence Synthesis | Preferences/Values | Health/Medicine | Health Outcomes